Indian Myeloma Congress 2026 Concludes at Amrita Hospital, Kochi

The Indian Myeloma Congress 2026 concluded at Amrita Hospital, Kochi, bringing together leading clinicians, researchers, scientists, trainees, and patient groups for three days of intensive academic exchange and collaboration. Hosted by Amrita Vishwa Vidyapeetham at the Amrita Health Sciences Campus, Kochi, the congress focused on advancing the understanding and management of multiple myeloma—a complex blood cancer arising from plasma cells in the bone marrow.

Around 500 participants from across India and abroad attended the congress, which showcased the latest advances in myeloma treatment and research. International and national experts presented updates on evolving therapeutic strategies, changing disease definitions, and innovations shaping myeloma care globally. Particular focus was given to next-generation treatments, including CAR-T cell therapy, bispecific T-cell engagers (BiTEs), and precision diagnostics such as MRD assessment, NGS, and cytogenetics.

A recurring theme across sessions was the importance of early diagnosis and timely initiation of treatment, especially in precursor states and high-risk disease. Multiple panel discussions examined when to intervene, how to stratify risk in the Indian context, and how emerging technologies can help personalise therapy while balancing access, toxicity, and cost.

The congress also placed strong emphasis on patient-centred care and engagement. Dedicated patient interaction sessions were held, during which experts including Dr. Nikhil Krishna Haridas, Dr. Manoj Unni, Dr. Sourabh, Dr. Sanju Cyriac, Dr. Abdul Majeed, Dr. Boban Thomas, Dr. Unni S. Pillai, Dr. Unnikrishnan, and Dr. Shaji K. Kumar interacted directly with myeloma patients and caregivers, addressing concerns related to treatment choices, quality of life, and long-term outcomes.

The three-day scientific programme spanned the entire myeloma spectrum—from precursor disease and smoldering myeloma to newly diagnosed, relapsed, and high-risk myeloma, as well as related conditions such as amyloidosis and other dysproteinemias. Sessions included expert lectures, debates, panel discussions, hands-on pre-conference workshops, trainee quizzes, oral paper presentations, and mentor–mentee interactions, fostering learning across generations of clinicians.

On the concluding day, key sessions were addressed by Dr. Neeraj Sidharthan, Head of the Department of Clinical Hematology, along with internationally renowned experts including Dr. Wee Joo Chng and Dr. Nikhil C. Munshi, who discussed the future of immunotherapy, sequencing strategies, treatment access in India and South Asia, and the long-term goal of achieving durable disease control—and potentially cure—in myeloma.

The congress was guided by a dedicated Organising Committee, comprising:
Lt Gen (Dr) Velu Nair; Dr. Neeraj Sidharthan; Col (Dr) Uday Yanamandra; Dr. Manoj Unni; Dr. Rema Ganapathi; Dr. Nikhil Krishna Haridas; Dr. Monisha Harimadhavan; Dr. Gayathri Sajeevan; and Dr. Suchitra Sivadas.

By the close of the congress, a shared message resonated clearly: myeloma care is entering a new era, shaped by innovation, early intervention, multidisciplinary collaboration, and compassionate, patient-focused approaches. The Indian Myeloma Congress at Amrita Hospital reaffirmed the institution’s growing role as a national and international hub for advanced hematology care, research, and education.